{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:12:05Z","timestamp":1789398725464,"version":"build-2803163510"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273335"],"award-info":[{"award-number":["82273335"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202024"],"award-info":[{"award-number":["82202024"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["2022LJ015"],"award-info":[{"award-number":["2022LJ015"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["24SF1900400"],"award-info":[{"award-number":["24SF1900400"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["25Y12800400"],"award-info":[{"award-number":["25Y12800400"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.phrs.2026.108347","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:39:24Z","timestamp":1784561964000},"page":"108347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The JAK1 inhibitor golidocitinib boosts therapeutic potency of DLL3-targeted CAR-T therapy for small cell lung cancer"],"prefix":"10.1016","volume":"231","author":[{"given":"Mengwei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huawei","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiting","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Qiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhui","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Litang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erpeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2026.108347_bib1","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.2025.0560","article-title":"Small cell lung cancer: a review","volume":"333","author":"Kim","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2026.108347_bib2","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/s41571-024-00914-x","article-title":"Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer","volume":"21","author":"Sen","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.phrs.2026.108347_bib3","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41568-025-00803-0","article-title":"Challenges of small cell lung cancer heterogeneity and phenotypic plasticity","volume":"25","author":"Simpson","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2026.108347_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2025.01.012","article-title":"Integrative spatial analysis reveals tumor heterogeneity and immune colony niche related to clinical outcomes in small cell lung cancer","volume":"43","author":"Chen","year":"2025","journal-title":"Cancer Cell."},{"key":"10.1016\/j.phrs.2026.108347_bib5","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/s43018-025-00996-1","article-title":"Advancing therapeutics in small-cell lung cancer","volume":"6","author":"Thomas","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.phrs.2026.108347_bib6","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s43018-025-00992-5","article-title":"The current and emerging immunotherapy paradigm in small-cell lung cancer","volume":"6","author":"Qin","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.phrs.2026.108347_bib7","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2026.108347_bib8","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2026.108347_bib9","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2026.108347_bib10","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1200\/JCO-25-02142","article-title":"Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial","volume":"44","author":"Rudin","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2026.108347_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN","volume":"7","author":"Paz-Ares","year":"2022","journal-title":"ESMO Open."},{"key":"10.1016\/j.phrs.2026.108347_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107924","article-title":"Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study","volume":"196","author":"Reck","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.phrs.2026.108347_bib13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-019-0745-2","article-title":"DLL3: an emerging target in small cell lung cancer","volume":"12","author":"Owen","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.phrs.2026.108347_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s12022-025-09854-3","article-title":"DLL3 Expression in Neuroendocrine Carcinomas and Neuroendocrine Tumours: Insights From a Multicentric Cohort of 1294 Pulmonary and Extrapulmonary Neuroendocrine Neoplasms","volume":"36","author":"Schmitt","year":"2025","journal-title":"Endocr. Pathol."},{"key":"10.1016\/j.phrs.2026.108347_bib15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12943-024-02012-z","article-title":"DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy","volume":"23","author":"Su","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.phrs.2026.108347_bib16","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13045-023-01464-y","article-title":"Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer","volume":"16","author":"Rudin","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.phrs.2026.108347_bib17","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S1470-2045(24)00249-3","article-title":"Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1\/2, first-in-human trial","volume":"25","author":"Tendler","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2026.108347_bib18","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1126\/scitranslmed.aac9459","article-title":"A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo","volume":"7","author":"Saunders","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.phrs.2026.108347_bib19","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2026.108347_bib20","doi-asserted-by":"crossref","DOI":"10.1172\/JCI166028","article-title":"IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models","volume":"133","author":"Jaspers","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2026.108347_bib21","first-page":"971","article-title":"CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer, Clinical Cancer Research: an Official Journal of the American","volume":"29","author":"Zhang","year":"2023","journal-title":"Assoc. Cancer Res."},{"key":"10.1016\/j.phrs.2026.108347_bib22","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/JLB.5MA0122-467R","article-title":"CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo","volume":"112","author":"Liu","year":"2022","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.phrs.2026.108347_bib23","first-page":"620","article-title":"Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions","volume":"73","author":"Megyesfalvi","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phrs.2026.108347_bib24","article-title":"697 A phase 1 study of AMG 119, a DLL3-targeting, chimeric antigen receptor (CAR) T cell therapy, in relapsed\/refractory small cell lung cancer (SCLC)","volume":"10","author":"Byers","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.phrs.2026.108347_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41573-025-01336-9","article-title":"Pharmacological targeting of the JAK-STAT pathway: new concepts and emerging indications","author":"Haikarainen","year":"2026","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.phrs.2026.108347_bib26","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jaci.2024.09.020","article-title":"JAK-STAT signaling pathway, immunodeficiency, inflammation, immune dysregulation, and inborn errors of immunity","volume":"155","author":"Samra","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.phrs.2026.108347_bib27","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/s41375-025-02569-8","article-title":"Malignant JAK-signaling: at the interface of inflammation and malignant transformation","volume":"39","author":"Perner","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.phrs.2026.108347_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/science.adf1329","article-title":"Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients","volume":"384","author":"Mathew","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.phrs.2026.108347_bib29","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/sj.bjc.6605068","article-title":"Alternative implication of CXCR4 in JAK2\/STAT3 activation in small cell lung cancer","volume":"100","author":"Pfeiffer","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2026.108347_bib30","article-title":"Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through Janus kinase-STAT3 signalling pathway","volume":"7","author":"Yang","year":"2012","journal-title":"PLoS. One"},{"key":"10.1016\/j.phrs.2026.108347_bib31","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1158\/1078-0432.CCR-13-1110","article-title":"The Janus kinases inhibitor AZD1480 attenuates growth of small cell lung cancers in vitro and in vivo","volume":"19","author":"Lee","year":"2013","journal-title":"Clinical Cancer Research Official Journal American Association Cancer Research"},{"key":"10.1016\/j.phrs.2026.108347_bib32","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1021\/acs.jmedchem.9b01392","article-title":"Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor","volume":"63","author":"Su","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108347_bib33","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s40265-024-02089-2","article-title":"Golidocitinib: First Approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2026.108347_bib34","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(23)00589-2","article-title":"Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study","volume":"25","author":"Song","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2026.108347_bib35","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood.2023021306","article-title":"CAR T cells and time-limited ibrutinib as treatment for relapsed\/refractory mantle cell lymphoma: the phase 2 TARMAC study","volume":"143","author":"Minson","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2026.108347_bib36","first-page":"611","volume":"32","author":"Armstrong","year":"2026","journal-title":"Ibrutinib PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy Preclinical Models Pancreatic Cancer Clinical Cancer Research Official Journal American Association Cancer Research"},{"key":"10.1016\/j.phrs.2026.108347_bib37","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41392-025-02422-5","article-title":"Limited SUMOylation inhibitor administration enhances eradication of Burkitt's lymphoma with CD19 CAR-T therapy","volume":"10","author":"Kotani","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.phrs.2026.108347_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010073","article-title":"BCL-2 mutant B7H6-CAR-T cells synergized with venetoclax for treating small cell lung cancer","volume":"13","author":"Zhang","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.phrs.2026.108347_bib39","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00262-024-03927-8","article-title":"Selective JAK2 pathway inhibition enhances anti-leukemic functionality in CD19 CAR-T cells","volume":"74","author":"Mitsuno","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.phrs.2026.108347_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba7308","article-title":"A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.phrs.2026.108347_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adr2151","article-title":"OX40-heparan sulfate binding facilitates CAR T cell penetration into solid tumors in mice","volume":"17","author":"Zhang","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.phrs.2026.108347_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2020.12.014","article-title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","volume":"39","author":"Gay","year":"2021","journal-title":"Cancer Cell."},{"key":"10.1016\/j.phrs.2026.108347_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2024.01.010","article-title":"Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade","volume":"42","author":"Nabet","year":"2024","journal-title":"Cancer Cell."},{"key":"10.1016\/j.phrs.2026.108347_bib44","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1158\/0008-5472.CAN-21-2964","article-title":"Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy","volume":"82","author":"Quintanal-Villalonga","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2026.108347_bib45","article-title":"Targeting FOXM1 reshapes antitumor immunity to attenuate small cell lung cancer progression","volume":"638","author":"Khan","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.phrs.2026.108347_bib46","article-title":"The pro-inflammatory cytokine IL6 suppresses mitochondrial function via the gp130-JAK1\/STAT1\/3-HIF1\u03b1\/ERR\u03b1 axis","volume":"44","author":"Xu","year":"2025","journal-title":"Cell. Rep."},{"key":"10.1016\/j.phrs.2026.108347_bib47","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2112006119","article-title":"Engineered IL13 variants direct specificity of IL13R\u03b12-targeted CAR T cell therapy","volume":"119","author":"Stern","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2026.108347_bib48","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.molmed.2024.10.016","article-title":"Harnessing IL-22 for metabolic health: promise and pitfalls","volume":"31","author":"Sajiir","year":"2024","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.phrs.2026.108347_bib49","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.phrs.2026.108347_bib50","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41577-025-01221-x","article-title":"Regulators of CD8+ T cell exhaustion","volume":"26","author":"Sun","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.phrs.2026.108347_bib51","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev-immunol-082223-044122","article-title":"Molecular Mechanisms Governing CD8 T Cell Differentiation and Checkpoint Inhibitor Response in Cancer","volume":"43","author":"Rausch","year":"2025","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.phrs.2026.108347_bib52","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/j.scib.2025.03.054","article-title":"T cell-based cancer immunotherapy: opportunities and challenges","volume":"70","author":"Ma","year":"2025","journal-title":"Sci. Bull. (Beijing)"},{"key":"10.1016\/j.phrs.2026.108347_bib53","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1365-2567.2000.00061.x","article-title":"Biological function of CD40 on human endothelial cells: costimulation with CD40 ligand and interleukin-4 selectively induces expression of vascular cell adhesion molecule-1 and P-selectin resulting in preferential adhesion of lymphocytes","volume":"100","author":"Kotowicz","year":"2000","journal-title":"Immunology"},{"key":"10.1016\/j.phrs.2026.108347_bib54","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science (New York N. Y. )"},{"key":"10.1016\/j.phrs.2026.108347_bib55","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1038\/s41418-025-01489-5","article-title":"Macrophage junctional adhesion molecule-like (JAML) protein promotes NLRP3 inflammasome activation in the development of atherosclerosis","volume":"32","author":"Cui","year":"2025","journal-title":"Cell. Death Differ."},{"key":"10.1016\/j.phrs.2026.108347_bib56","doi-asserted-by":"crossref","first-page":"15338","DOI":"10.1038\/ncomms15338","article-title":"Notch-mediated conversion of activated T cells into stem cell memory-like T cells for adoptive immunotherapy","volume":"8","author":"Kondo","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2026.108347_bib57","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1158\/0008-5472.CAN-19-1196","article-title":"The NOTCH-FOXM1 Axis Plays a Key Role in Mitochondrial Biogenesis in the Induction of Human Stem Cell Memory-like CAR-T Cells","volume":"80","author":"Kondo","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2026.108347_bib58","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1158\/2767-9764.CRC-21-0034","article-title":"Rejuvenating Effector\/Exhausted CAR T Cells to Stem Cell Memory-Like CAR T Cells By Resting Them in the Presence of CXCL12 and the NOTCH Ligand","volume":"1","author":"Ando","year":"2021","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.phrs.2026.108347_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2020.05.008","article-title":"Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity","volume":"27","author":"Zhu","year":"2020","journal-title":"Cell. Stem Cell."},{"key":"10.1016\/j.phrs.2026.108347_bib60","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s40164-024-00588-2","article-title":"Disrupting Notch signaling related HES1 in myeloid cells reinvigorates antitumor T cell responses","volume":"13","author":"Kim","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.phrs.2026.108347_bib61","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.phrs.2026.108347_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107928","article-title":"Reprogramming CAR-T cells: Targeting SLC transporters for tumor microenvironment adaptation","volume":"220","author":"Perucha","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2026.108347_bib63","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1038\/s41467-023-42714-4","article-title":"Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin","volume":"14","author":"Tang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2026.108347_bib64","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2025017682","article-title":"Serum free fatty acid promotes tumor progression and predicts golidocitinib sensitivity in peripheral T-cell lymphoma","author":"Qin","year":"2026","journal-title":"Blood Adv."},{"key":"10.1016\/j.phrs.2026.108347_bib65","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1158\/1078-0432.CCR-20-1739","article-title":"Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy","volume":"26","author":"Huarte","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2026.108347_bib66","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbrc.2022.01.070","article-title":"Ruxolitinib reduces severe CRS response by suspending CAR-T cell function instead of damaging CAR-T cells","volume":"595","author":"Xu","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2026.108347_bib67","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1158\/1078-0432.CCR-13-1110","article-title":"The Janus kinases inhibitor AZD1480 attenuates growth of small cell lung cancers in vitro and in vivo","volume":"19","author":"Lee","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2026.108347_bib68","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.neo.2015.01.003","article-title":"JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth","volume":"17","author":"Sen","year":"2015","journal-title":"Neoplasia"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:56:45Z","timestamp":1789397805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826002628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":68,"alternative-id":["S1043661826002628"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108347","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The JAK1 inhibitor golidocitinib boosts therapeutic potency of DLL3-targeted CAR-T therapy for small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108347","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108347"}}